Literature DB >> 14746524

Human papillomavirus vaccines and prevention of cervical cancer.

Kathrin U Jansen1, Alan R Shaw.   

Abstract

Cervical cancer and precancerous cervical lesions constitute a major problem in women's health. Every year 470,000 cases of cervical cancer are diagnosed worldwide, and about half the women afflicted will die. In the United States alone, approximately 14,000 cases of cervical cancer are diagnosed each year despite the availability of screening and access to high-quality gynecological care. With the confirmation that cervical cancer is caused by an infectious agent, human papillomavirus, the possibility of fighting this disease with either prophylactic or therapeutic vaccination arose. This review describes advances in vaccine development and very promising first results for prophylactic vaccination against cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14746524     DOI: 10.1146/annurev.med.55.091902.103520

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  7 in total

1.  Predicting pediatricians' communication with parents about the human papillomavirus (hpv) vaccine: an application of the theory of reasoned action.

Authors:  Anthony J Roberto; Janice L Krieger; Mira L Katz; Ryan Goei; Parul Jain
Journal:  Health Commun       Date:  2011-06

2.  Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18.

Authors:  Dennis Dias; Jeff Van Doren; Sonela Schlottmann; Sheri Kelly; Derek Puchalski; Wanda Ruiz; Patricia Boerckel; Joseph Kessler; Joseph M Antonello; Tina Green; Martha Brown; Judith Smith; Narendra Chirmule; Eliav Barr; Kathrin U Jansen; Mark T Esser
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

Review 3.  Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).

Authors:  M Asif A Siddiqui; Caroline M Perry
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Recent advances in human papillomavirus vaccines.

Authors:  Ali Mahdavi; Bradley J Monk
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

Review 5.  Human papillomavirus type 16 E5 protein as a therapeutic target.

Authors:  Sang-Woo Kim; Joo-Sung Yang
Journal:  Yonsei Med J       Date:  2006-02-28       Impact factor: 2.759

6.  Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

Authors:  Joakim Dillner; Susanne K Kjaer; Cosette M Wheeler; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; F Xavier Bosch; Elmar A Joura; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine T Bryan; Roger Maansson; Shuang Lu; Scott Vuocolo; Teresa M Hesley; Eliav Barr; Richard Haupt
Journal:  BMJ       Date:  2010-07-20

7.  HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo.

Authors:  Shu-Jie Liao; Dong-Rui Deng; Dan Zeng; Ling Zhang; Xiao-Ji Hu; Wei-Na Zhang; Li Li; Xue-Feng Jiang; Chang-Yu Wang; Jian-Feng Zhou; Shi-Xuan Wang; Han-Wang Zhang; Ding Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-10-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.